FEMY
Price
$1.71
Change
+$0.08 (+4.91%)
Updated
Oct 20, 11:08 AM (EDT)
Capitalization
13.65M
28 days until earnings call
Intraday BUY SELL Signals
LUCD
Price
$0.31
Change
-$0.07 (-18.42%)
Updated
Oct 20, 11:14 AM (EDT)
Capitalization
72.06M
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FEMY vs LUCD

FEMY vs LUCD Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
FEMY vs. LUCD commentary
Oct 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FEMY is a Hold and LUCD is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for FEMY with price predictions
Oct 19, 2026

FEMY's RSI Oscillator sits in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where FEMY advanced for three days, in 152 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

FEMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for FEMY turned negative on September 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 41 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FEMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for FEMY entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.387) is normal, around the industry mean (4.887). P/E Ratio (-0.599) is within average values for comparable stocks, (35.995). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (3.324) is also within normal values, averaging (56.074).

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. FEMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FEMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
a Summary for LUCD with price predictions
Oct 19, 2026

LUCD sees MACD Histogram crosses below signal line

LUCD saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 40 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LUCD as a result. In 81 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUCD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for LUCD entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUCD advanced for three days, in 197 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

LUCD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. LUCD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.595) is normal, around the industry mean (2.908). P/E Ratio (-0.920) is within average values for comparable stocks, (2.616). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (21.645) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUCD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
FEMYLUCD
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
N/A
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 28 days ago
82%
Bullish Trend 13 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
COMPARISON
Comparison
Oct 20, 2026
Stock price -- (FEMY: $1.63 vs. LUCD: $0.38)
Brand notoriety: FEMY and LUCD are both not notable
FEMY represents the Pharmaceuticals: Other, while LUCD is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: FEMY: 8% vs. LUCD: 298%
Market capitalization -- FEMY: $13.65M vs. LUCD: $72.06M
FEMY [@Pharmaceuticals: Other] is valued at $13.65M. LUCD’s [@Medical/Nursing Services] market capitalization is $72.06M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $153.03B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $180.06B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.1B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FEMY’s FA Score shows that 1 FA rating(s) are green while LUCD’s FA Score has 1 green FA rating(s).

  • FEMY’s FA Score: 1 green, 4 red.
  • LUCD’s FA Score: 1 green, 4 red.
According to our system of comparison, FEMY is a better buy in the long-term than LUCD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FEMY’s TA Score shows that 3 TA indicator(s) are bullish while LUCD’s TA Score has 4 bullish TA indicator(s).

  • FEMY’s TA Score: 3 bullish, 3 bearish.
  • LUCD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both FEMY and LUCD are a good buy in the short-term.

Price Growth

FEMY (@Pharmaceuticals: Other) experienced а -6.86% price change this week, while LUCD (@Medical/Nursing Services) price change was -36.83% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.50%. For the same industry, the average monthly price growth was -2.91%, and the average quarterly price growth was +7.01%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.67%. For the same industry, the average monthly price growth was -9.97%, and the average quarterly price growth was -11.02%.

Reported Earning Dates

FEMY is expected to report earnings on Nov 17, 2026.

LUCD is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (+0.50% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical/Nursing Services (-3.67% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
FEMY
Daily Signal:
Gain/Loss:
LUCD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
YALA5.610.07
+1.26%
Yalla Group Limited
KMB105.41-0.16
-0.15%
Kimberly-Clark Corp
SBFG29.33-0.19
-0.66%
SB Financial Group
ICUI161.24-1.75
-1.07%
ICU Medical
LHAI0.81-0.04
-4.35%
Linkhome Holdings Inc

FEMY and

Correlation & Price change

A.I.dvisor tells us that FEMY and OFIX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FEMY and OFIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FEMY
1D Price
Change %
FEMY100%
-1.21%
OFIX - FEMY
30%
Poorly correlated
+2.24%
CSTL - FEMY
30%
Poorly correlated
+0.64%
LUCD - FEMY
30%
Poorly correlated
-21.05%
OM - FEMY
29%
Poorly correlated
-3.55%
GH - FEMY
29%
Poorly correlated
-0.45%
More

LUCD and

Correlation & Price change

A.I.dvisor tells us that LUCD and FEMY have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LUCD and FEMY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LUCD
1D Price
Change %
LUCD100%
-21.05%
FEMY - LUCD
30%
Poorly correlated
-1.21%
BFLY - LUCD
28%
Poorly correlated
+3.03%
CNMD - LUCD
27%
Poorly correlated
-1.43%
CRL - LUCD
27%
Poorly correlated
-0.04%
ELMD - LUCD
26%
Poorly correlated
-0.07%
More